EMVision Medical Devices (ASX:EMV) is set to expand its emu brain scanner pivotal validation trial, adding an acute ischemia detection feature to the study following progress in its parallel continuous innovation study, according to a Monday filing with the Australian bourse.
Trial recruitment has surpassed 125 total patients, as of early May, across eight active US and Australian hospitals, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.